Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1540-1549

  Demers, Mélanie ^a,b   Ho Tin Noé, Benoit ^a,b,c   Schatzberg, Daphne ^a   Yang, Janie J ^a   Wagner, Denisa D ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICROSPHERE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLEEDING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HISTOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CARCINOMA, LEWIS LUNG; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PACLITAXEL; THROMBOCYTOPENIA; TISSUE DISTRIBUTION;

EID: 79952216172     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2038     Document Type: Article

References (32)

1. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007;1776:175-92. (Pubitemid 350061071)
2. Langer R. Drug delivery and targeting. Nature 1998;392:5-10. (Pubitemid 28215187)
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60. (Pubitemid 350223348)
4. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202. (Pubitemid 30650733)
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
6. Klosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, Moen I, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 2009;4:e8149.
7. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6:3056-61. (Pubitemid 30637728)
8. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11:7851-60. (Pubitemid 41611630)
9. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
10. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5.
11. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18.
12. Italiano JE Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: proand antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227-33. (Pubitemid 351213404)
13. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 2006;103:855-60. (Pubitemid 43212187)
14. Goerge T, Ho-Tin-Noe B, Carbo C, Benarafa C, Remold-O'Donnell E, Zhao BQ, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008;111:4958-64.
15. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008;68:6851-8.
16. Ho-Tin-Noe B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009;175:1699-708.
17. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
18. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001;97:1378-87. (Pubitemid 32183762)
19. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem 2004;279:51057-67. (Pubitemid 40017847)
20. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
21. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
22. Attia MA, Weiss DW. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 1966;26:1787-800.
23. Langley RR, Russell J, Eppihimer MJ, Alexander SJ, Gerritsen M, Specian RD, et al. Quantification of murine endothelial cell adhesion molecules in solid tumors. Am J Physiol 1999;277:H1156-66.
24. Tipton JM. Side effects of cancer chemotherapy. Handbook of cancer chemotherapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2003. p. 561-80.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
27. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201. (Pubitemid 28183208)
28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
29. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol 2002;42:163-71.
30. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 2009;46:S26-32.
31. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-104. (Pubitemid 38326225)
32. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15. (Pubitemid 38111215)